Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT

Annalisa Paviglianiti; Erick Xavier; Annalisa Ruggeri; Patrice Ceballos; Eric Deconinck; Jan J Cornelissen; Stephanie Nguyen-Quoc; Natacha Maillard; Guillermo Sanz; Pierre-Simon Rohrlich; Laurent Garderet; Fernanda Volt; Vanderson Rocha; Nicolaus Kroeger; Eliane Gluckman; Nathalie Fegueux; Mohamad Mohty

doi:10.3324/haematol.2015.138917

Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT

Standard

Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT. / Paviglianiti, Annalisa; Xavier, Erick; Ruggeri, Annalisa; Ceballos, Patrice; Deconinck, Eric; Cornelissen, Jan J; Nguyen-Quoc, Stephanie; Maillard, Natacha; Sanz, Guillermo; Rohrlich, Pierre-Simon; Garderet, Laurent; Volt, Fernanda; Rocha, Vanderson; Kroeger, Nicolaus; Gluckman, Eliane; Fegueux, Nathalie; Mohty, Mohamad.

in: HAEMATOLOGICA, Jahrgang 101, Nr. 9, 09.2016, S. 1120-7.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Paviglianiti, A, Xavier, E, Ruggeri, A, Ceballos, P, Deconinck, E, Cornelissen, JJ, Nguyen-Quoc, S, Maillard, N, Sanz, G, Rohrlich, P-S, Garderet, L, Volt, F, Rocha, V, Kroeger, N, Gluckman, E, Fegueux, N & Mohty, M 2016, 'Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT', HAEMATOLOGICA, Jg. 101, Nr. 9, S. 1120-7. https://doi.org/10.3324/haematol.2015.138917

APA

Paviglianiti, A., Xavier, E., Ruggeri, A., Ceballos, P., Deconinck, E., Cornelissen, J. J., Nguyen-Quoc, S., Maillard, N., Sanz, G., Rohrlich, P-S., Garderet, L., Volt, F., Rocha, V., Kroeger, N., Gluckman, E., Fegueux, N., & Mohty, M. (2016). Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT. HAEMATOLOGICA, 101(9), 1120-7. https://doi.org/10.3324/haematol.2015.138917

Vancouver

Paviglianiti A, Xavier E, Ruggeri A, Ceballos P, Deconinck E, Cornelissen JJ et al. Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT. HAEMATOLOGICA. 2016 Sep;101(9):1120-7. https://doi.org/10.3324/haematol.2015.138917

Bibtex

@article{a0c4293b5d1f46afa24fae8ebfb8e83d,

title = "Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT",

abstract = "Although allogeneic stem cell transplantation is not a standard therapy for multiple myeloma, some patients can benefit from this intense therapy. There are few reports on outcomes after umbilical cord blood transplantation in multiple myeloma, and investigation of this procedure is warranted. We retrospectively analyzed 95 patients, 85 with multiple myeloma and 10 with plasma cell leukemia, receiving single or double umbilical cord blood transplantation from 2001 to 2013. Median follow up was 41 months. The majority of patients received a reduced intensity conditioning. The cumulative incidence of neutrophil engraftment was 97%±3% at 60 days, and that of 100-day acute graft-versus-host disease grade II-IV was 41%±5%. Chronic graft-versus-host disease at two years was 22%±4%. Relapse and non-relapse mortality was 47%±5% and 29%±5% at three years, respectively. Three-year progression-free survival and overall survival were 24%±5% and 40%±5%, respectively. Anti-thymocyte globulin was associated with decreased incidence of acute graft-versus-host disease, higher non-relapse mortality, decreased overall and progression-free survival. Patients with high cytogenetic risk had higher relapse, and worse overall and progression-free survival. In conclusion, umbilical cord blood transplantation is feasible for multiple myeloma patients.",

keywords = "Adult, Aged, Combined Modality Therapy, Cord Blood Stem Cell Transplantation, Female, Follow-Up Studies, Graft Survival, Graft vs Host Disease, Humans, Male, Middle Aged, Mortality, Multiple Myeloma, Recurrence, Registries, Retrospective Studies, Treatment Outcome, Unrelated Donors, Young Adult, Journal Article",

author = "Annalisa Paviglianiti and Erick Xavier and Annalisa Ruggeri and Patrice Ceballos and Eric Deconinck and Cornelissen, {Jan J} and Stephanie Nguyen-Quoc and Natacha Maillard and Guillermo Sanz and Pierre-Simon Rohrlich and Laurent Garderet and Fernanda Volt and Vanderson Rocha and Nicolaus Kroeger and Eliane Gluckman and Nathalie Fegueux and Mohamad Mohty",

note = "Copyright{\textcopyright} Ferrata Storti Foundation.",

year = "2016",

month = sep,

doi = "10.3324/haematol.2015.138917",

language = "English",

volume = "101",

pages = "1120--7",

journal = "HAEMATOLOGICA",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "9",

}

RIS

TY - JOUR

T1 - Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT

AU - Paviglianiti, Annalisa

AU - Xavier, Erick

AU - Ruggeri, Annalisa

AU - Ceballos, Patrice

AU - Deconinck, Eric

AU - Cornelissen, Jan J

AU - Nguyen-Quoc, Stephanie

AU - Maillard, Natacha

AU - Sanz, Guillermo

AU - Rohrlich, Pierre-Simon

AU - Garderet, Laurent

AU - Volt, Fernanda

AU - Rocha, Vanderson

AU - Kroeger, Nicolaus

AU - Gluckman, Eliane

AU - Fegueux, Nathalie

AU - Mohty, Mohamad

PY - 2016/9

Y1 - 2016/9

N2 - Although allogeneic stem cell transplantation is not a standard therapy for multiple myeloma, some patients can benefit from this intense therapy. There are few reports on outcomes after umbilical cord blood transplantation in multiple myeloma, and investigation of this procedure is warranted. We retrospectively analyzed 95 patients, 85 with multiple myeloma and 10 with plasma cell leukemia, receiving single or double umbilical cord blood transplantation from 2001 to 2013. Median follow up was 41 months. The majority of patients received a reduced intensity conditioning. The cumulative incidence of neutrophil engraftment was 97%±3% at 60 days, and that of 100-day acute graft-versus-host disease grade II-IV was 41%±5%. Chronic graft-versus-host disease at two years was 22%±4%. Relapse and non-relapse mortality was 47%±5% and 29%±5% at three years, respectively. Three-year progression-free survival and overall survival were 24%±5% and 40%±5%, respectively. Anti-thymocyte globulin was associated with decreased incidence of acute graft-versus-host disease, higher non-relapse mortality, decreased overall and progression-free survival. Patients with high cytogenetic risk had higher relapse, and worse overall and progression-free survival. In conclusion, umbilical cord blood transplantation is feasible for multiple myeloma patients.

AB - Although allogeneic stem cell transplantation is not a standard therapy for multiple myeloma, some patients can benefit from this intense therapy. There are few reports on outcomes after umbilical cord blood transplantation in multiple myeloma, and investigation of this procedure is warranted. We retrospectively analyzed 95 patients, 85 with multiple myeloma and 10 with plasma cell leukemia, receiving single or double umbilical cord blood transplantation from 2001 to 2013. Median follow up was 41 months. The majority of patients received a reduced intensity conditioning. The cumulative incidence of neutrophil engraftment was 97%±3% at 60 days, and that of 100-day acute graft-versus-host disease grade II-IV was 41%±5%. Chronic graft-versus-host disease at two years was 22%±4%. Relapse and non-relapse mortality was 47%±5% and 29%±5% at three years, respectively. Three-year progression-free survival and overall survival were 24%±5% and 40%±5%, respectively. Anti-thymocyte globulin was associated with decreased incidence of acute graft-versus-host disease, higher non-relapse mortality, decreased overall and progression-free survival. Patients with high cytogenetic risk had higher relapse, and worse overall and progression-free survival. In conclusion, umbilical cord blood transplantation is feasible for multiple myeloma patients.

KW - Adult

KW - Aged

KW - Combined Modality Therapy

KW - Cord Blood Stem Cell Transplantation

KW - Female

KW - Follow-Up Studies

KW - Graft Survival

KW - Graft vs Host Disease

KW - Humans

KW - Male

KW - Middle Aged

KW - Mortality

KW - Multiple Myeloma

KW - Recurrence

KW - Registries

KW - Retrospective Studies

KW - Treatment Outcome

KW - Unrelated Donors

KW - Young Adult

KW - Journal Article

U2 - 10.3324/haematol.2015.138917

DO - 10.3324/haematol.2015.138917

M3 - SCORING: Journal article

C2 - 27229716

VL - 101

SP - 1120

EP - 1127

JO - HAEMATOLOGICA

JF - HAEMATOLOGICA

SN - 0390-6078

IS - 9

ER -